Momenta receives patent for methods to evaluate enoxaparin

Oct 26 2010NewsGuard 100/100 Score

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,816,144, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping". The patent includes claims to methods of analyzing and processing enoxaparin by analyzing chain sequence information.

"This patent adds to our intellectual property estate related to the characterization of enoxaparin," said Craig Wheeler, President and CEO of Momenta. "We believe this patent strengthens our portfolio of patents and pending applications that provide intellectual property protection around enoxaparin sodium injection USP, also known as generic Lovenox®." 

Source: Momenta Pharmaceuticals, Inc. 

Posted in: Medical Patent News

Tags: , , , , ,

Comments (0)

Suggested Reading

Expanded access to weight-loss drugs could save thousands of lives
Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing
Diabetes drugs may reduce risk of opioid overdose and alcohol intoxication
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options
AI-designed drug ISM5939 granted IND clearance for cancer clinical trials
Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials
CAR T cell therapy breakthroughs bring new hope for treating solid tumors

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder